Top-News
Pharmazeutika USA

AIM ImmunoTech News

Aktie
WKN:  A2PREX ISIN:  US00901B1052 US-Symbol:  AIM
0,346 €
-0,018 €
-4,95%
16.05.24 16:05:52
Handeln Depot/Watchlist
Aktienanzahl *
48,84 Mio.
Marktkapitalisierung *
17,53 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 03.04.2024

Unternehmensmeldungen

09.05.24 - GlobeNewswire
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) announced today that management will host a conference call ...
06.05.24 - GlobeNewswire
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced the successfully completion of cGMP ...
29.04.24 - GlobeNewswire
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Next safety cohort to begin escalated dosing soon
10.04.24 - GlobeNewswire
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM”) today announced top-line interim data indicating that combining Ampligen ...
02.04.24 - GlobeNewswire
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Year marked by growing body of promising data demonstrating Ampligen’s potential to address multiple high-​value indications
26.03.24 - GlobeNewswire
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) announced today that management will host a conference ...
25.03.24 - GlobeNewswire
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
Data demonstrate compelling evidence of the immune-​stimulatory properties linked to TLR-3 activation through Ampligen
07.03.24 - GlobeNewswire
AIM ImmunoTech Announces Launch of CEO Corner Platform
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress
29.02.24 - GlobeNewswire
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
Company continues progress across Ampligen ® clinical development programs
14.02.24 - GlobeNewswire
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
Phase 1b portion of the study expected to be completed within six months
24.01.24 - GlobeNewswire
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
Subject enrollment is expected in Q1 2024
22.01.24 - GlobeNewswire
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands
10.01.24 - GlobeNewswire
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands
27.11.23 - GlobeNewswire
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039
15.11.23 - GlobeNewswire
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
– Highlights continued execution across Ampligen ® clinical development programs
09.11.23 - GlobeNewswire
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”), announced today that management will host a conference ...
17.10.23 - GlobeNewswire
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs
OCALA, Fla., Oct. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has entered into an agreement with Azenova, LLC ...
11.09.23 - GlobeNewswire
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at ...
15.08.23 - GlobeNewswire
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
– Continued operational execution across pipeline towards multiple clinical and regulatory value-​driving milestones expected in the second half of 2023
09.08.23 - GlobeNewswire
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call ...

Newssuche

Videos

newspaper
08:55 Uhr +11,95%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »